Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

Roche

Status: Completed

Conditions: Renal Impairment; Renal Anemia of Chronic Kidney Disease

Treatments: Drug: Methoxy polyethylene glycol epoetin beta

Study type: Observational

Funder types: Industry

Identifiers

NCT02596945

ML22000

Details and patient eligibility

About

This non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis. Participants who were prescribed methoxy polyethylene glycol epoetin beta by their doctor and who meet the selection criteria were to be enrolled and documented in this study for a period of 9 months of treatment with methoxy polyethylene glycol epoetin beta with respect to efficacy, safety and usability.

Enrollment: 223 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants on peritoneal dialysis
• Need for Erythropoiesis Stimulating Agent (ESA) therapy
• Prescription of methoxy polyethylene glycol epoetin beta by the doctor

Exclusion criteria

N/A

Trial design

223 participants in 1 patient group

Peritoneal Dialysis participants

Description:

Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.

Treatment:

Drug: Methoxy polyethylene glycol epoetin beta